This session discusses the successes of the accelerated approval pathway for the patient community, reform efforts underway, and how stakeholders are balancing the utility of expedited approval programs with concerns raised about their effectiveness.

Value-based payment has long been viewed as a key approach to facilitating access while ensuring accountability for costs and quality. But when it comes to transformative technologies, such as gene therapies that carry price tags much higher than conventional therapies, are value-based payment models still the right approach?

Although we've come a long way, much work remains to be done to ensure that determinations of the value of cell and gene therapies integrate the perspectives of those they are intended to help: Patients.